Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Blinded, Randomized Study With Aprocitentan in Subjects With Uncontrolled Blood Pressure and Chronic Kidney Disease Stage 3 or 4

Next Previous
X
Search
Trial Profile

Multi-center, Blinded, Randomized Study With Aprocitentan in Subjects With Uncontrolled Blood Pressure and Chronic Kidney Disease Stage 3 or 4

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprocitentan (Primary)
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms INSPIRE-CKD
  • Sponsors Idorsia Pharmaceuticals

    • Most Recent Events

    • 01 Feb 2020 This trial has been Discontinued in Spain, as per European Clinical Trials Database record.
    • 20 Jan 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 17 Jan 2020 This trial was discontinued in Czech Republic and Hungary according to EudraCT database

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top